Zepbound (tirzepatide)

At a glance

Molecule

tirzepatide

Approved for

chronic weight management

Form

weekly injection

Self-pay, direct from manufacturer

from $299/month

Pivotal trial result

22.5% mean weight reduction

Prescription required

Yes — as for every GLP-1 receptor agonist

That 22.5% is a group average, and averages in these trials sit on top of a wide spread — some participants lost a great deal more, some lost nothing, and a share of the placebo arm lost weight too. Rather than restate the mean as though it were a forecast, we show the spread behind Zepbound’s trial average, including how many people reached each threshold and what the comparator arm did.

Also approved for obstructive sleep apnoea in adults with obesity.

The confusion worth clearing up

Zepbound and Mounjaro are the same molecule, approved for different uses.

The class, the molecule and the brand name are three different levels, and most “versus” questions in this category dissolve once they are separated — which level of that Zepbound belongs to, and what it is being compared against is the thing worth settling first.

What it costs

Self-pay KwikPen: $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg and above) per month. Single-dose pens without coverage: $499/month.

Verified 2026-07-25 against Eli Lilly (Zepbound). Prices in this category change frequently — confirm before you buy.

That is the manufacturer’s direct price. How it compares against insurance, Medicare and telehealth memberships — which carry a membership fee on top of the medication — is set out in the same figure reached four other ways.

Price is one of the few things about Zepbound that belongs to the molecule rather than to the brand. tirzepatide is sold in more than one form, and which form is prescribed moves the figure before any seller does. Where Zepbound sits against every tirzepatide price we have verified is set out form by form, with each provider’s membership fee added to its medication price.

What this page deliberately leaves out

Side-effect rates, contraindications, dosing schedules, and drug interactions for Zepbound are on its FDA-approved label, published on DailyMed. We are not going to reproduce them here from anywhere else, because a drug page that looks complete but was assembled second-hand is more dangerous than one that is visibly partial.

What we do cover, at the level of the class rather than the product:

• Side effects — what is common, what is serious, and the boxed warning.
• Dosing and titration — why doses start low and climb, and what happens at each step.
• How these medications work — the four mechanisms, and why they also explain the side effects.

Questions people ask about Zepbound

Is Zepbound a GLP-1?

Yes. Zepbound is tirzepatide, a GLP-1 receptor agonist, approved for chronic weight management and given as a weekly injection. "GLP-1" is the drug class; tirzepatide is the molecule; Zepbound is the brand name that molecule is sold under for this use.

Is Zepbound the same as Mounjaro?

They are the same molecule — tirzepatide — approved for different uses. Zepbound is approved for chronic weight management; Mounjaro for type 2 diabetes. That difference is not pharmacological, but it decides how an insurer treats each one, which is usually the practical question hiding inside "which is better".

Do you need a prescription for Zepbound?

Yes, in the United States, as for every GLP-1 receptor agonist. Anything sold as Zepbound without a prescription is not Zepbound, whatever the label says — and a product bought outside the prescribing chain carries none of the manufacturing verification the approved product does.

How much does Zepbound cost?

Zepbound is published at from $299 a month self-pay direct from the manufacturer, verified 2026-07-25. That figure is the manufacturer's published price, not what you will necessarily pay: insurance, telehealth membership fees and dose all change the total.

How much weight did people lose on Zepbound in its trial?

SURMOUNT-1, NEJM 2022 reported a mean body-weight reduction of 22.5% (vs. 2.4% placebo). That is a group average from one trial over a fixed period, not a forecast for any individual, and trials of different products were run separately rather than head to head.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.